Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pharmacokinetics of Fidaxomicin”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableEnded earlyNCT01533844
What this trial is testing

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

Who this might be right for
Clostridium Difficile
Astellas Pharma Europe B.V. 1
Early research (Phase 1)Study completedNCT02083627
What this trial is testing

Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Who this might be right for
Drug-Drug Interaction (DDI)Intestinal AbsorptionHealthy Subjects+2 more
Astellas Pharma Europe B.V. 25
Post-approval studies (Phase 4)Study completedNCT02437591
What this trial is testing

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Who this might be right for
Inflammatory Bowel Disease (IBD)Clostridium Difficile Infection (CDI)
Astellas Pharma Europe Ltd. 25
Early research (Phase 1)Study completedNCT01813448
What this trial is testing

Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Who this might be right for
Pharmacokinetics of FidaxomicinHealthy Subjects
Astellas Pharma Global Development, Inc. 36
Testing effectiveness (Phase 2)Study completedNCT01591863
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Who this might be right for
Clostridium Difficile-associated Diarrhea
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 38
Large-scale testing (Phase 3)Study completedNCT02179658
What this trial is testing

Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Who this might be right for
Clostridium Difficile
Astellas Pharma Inc 210